Fanizza, J.; Bencardino, S.; Allocca, M.; Furfaro, F.; Zilli, A.; Parigi, T. L.; Fiorino, G.; Peyrin-Biroulet, L.; Danese, S.; D’Amico, F. Inflammatory Bowel Disease and Colorectal Cancer. Preprints2024, 2024072568. https://doi.org/10.20944/preprints202407.2568.v1
APA Style
Fanizza, J., Bencardino, S., Allocca, M., Furfaro, F., Zilli, A., Parigi, T. L., Fiorino, G., Peyrin-Biroulet, L., Danese, S., & D’Amico, F. (2024). Inflammatory Bowel Disease and Colorectal Cancer. Preprints. https://doi.org/10.20944/preprints202407.2568.v1
Chicago/Turabian Style
Fanizza, J., Silvio Danese and Ferdinando D’Amico. 2024 "Inflammatory Bowel Disease and Colorectal Cancer" Preprints. https://doi.org/10.20944/preprints202407.2568.v1
Abstract
Patients with inflammatory bowel diseases (IBD), including both ulcerative colitis (UC) and Crohn's disease (CD), are at a higher risk of developing colorectal cancer (CRC). However, advancements in endoscopic imaging techniques, integrated surveillance programs, and improved medical therapies have led to a decrease in the incidence of CRC among IBD patients. Currently, the management of patients with IBD who have a history of or ongoing active malignancy is an unmet need. This involves balancing the risk of cancer recurrence/progression with the potential exacerbation of IBD if the medications are discontinued. The objective of this review is to provide an updated summary of the epidemiology, causes, risk factors, and surveillance approaches for CRC in individuals with IBD, and to offer practical guidance on managing IBD patients with history of previous or active cancer.
Medicine and Pharmacology, Gastroenterology and Hepatology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
